Development of a high-throughput ELISA assay for platelet function testing using platelet-rich plasma or whole blood

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 392-401

  Salles, Isabelle I ^a,b   Broos, Katleen ^a   Fontayne, Alexandre ^a   Szántó, Tímea ^a   Ruan, Changgeng ^c   Nurden, Alan T ^d   Vanhoorelbeke, Karen ^a   Deckmyn, Hans ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c SOOCHOW UNIVERSITY   (China)

^d Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

Platelet activation; Platelet ELISA; Platelet function tests

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; GLYCOPROTEIN IB ALPHA; MONOCLONAL ANTIBODY; PADGEM PROTEIN;

ARTICLE; BLOOD VOLUME; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; ALPROSTADIL; ANTIBODIES, MONOCLONAL; ARACHIDONIC ACID; BLOOD PLATELETS; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLYCOPROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOGLOBULINS; INTEGRIN ALPHA2; INTEGRIN BETA3; OBSERVER VARIATION; P-SELECTIN; PEPTIDES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; S-NITROSO-N-ACETYLPENICILLAMINE;

EID: 77955450008     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-07-0505     Document Type: Article

References (47)

1. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
2. Lecut C, Schoolmeester A, Kuijpers MJ, et al. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004; 24: 1727-1733.
3. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412.
4. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1: 1602-1612.
5. Deckmyn H, Vanhoorelbeke K, Ulrichts H, et al. Amplification loops and signal transduction pathways. eds. Leuven University Press 2003; pp. 75-91.
6. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814.
7. Deckmyn H, Ulrichts H, Van De Walle G, et al. Platelet antigens and their function. Vox Sanguinis 2004; 87 (Suppl 2): 105-111.
8. Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996; 72: 171-191.
9. Mitchell JA, Ali F, Bailey L, et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 2008; 93: 141-147.
10. Jones CI, Garner SF, Angenent W, et al. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. J Thromb Haemost 2007; 5: 1756-1765.
11. Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Sem Thromb Hemost 2005; 31: 393-399.
12. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology 2005; 10: 177-181.
13. Zwierzina WD, Kunz F. A method of testing platelet aggregation in native whole blood. Thromb Res 1985; 38: 91-100.
14. Shah U, Ma AD. Tests of platelet function. Curr Opin Hematol 2007; 14: 432-437.
15. Moran N, Kiernan A, Dunne E, et al. Monitoring modulators of platelet aggregation in a microtiter plate assay. Analyt Biochem 2006; 357: 77-84.
16. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103 (3 Suppl): 20A-26A.
17. Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
18. Peace AJ, Tedesco AF, Foley DP, et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 6: 2027-2034.
19. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-660.
20. Wu G, Xi X, Li P, et al. Preparation of a monoclonal antibody, SZ-51, that recognizes an alpha-granule membrane protein (GMP-140) on the surface of activated human platelets. Nouv Rev Franc Hematol 1990; 32: 231-235.
21. Deckmyn H, Stanssens P, Hoet B, et al. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. Br J Haematol 1994; 87: 562-571.
22. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: 255-268.
23. Stenberg PE, McEver RP, Shuman MA, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
24. Chung AW, Jurasz P, Hollenberg MD, et al. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 2002; 135: 1123-1132.
25. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscl Thromb Vasc Biol 2000; 20: 1347-1353.
26. Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coag Fibrinol 1994; 5: 97-119.
27. Milet-Marsal S, Breillat C, Peyruchaud O, et al. Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 655-662.
28. Holmes MB, Sobel BE, Howard DB, Schneider DJ. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999; 95: 75-82.
29. Dropinski J, Jakiela B, Sanak M, et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007; 98: 201-209.
30. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.
31. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23: 1941-1947.
32. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
33. Metzelaar MJ, Korteweg J, Sixma JJ, et al. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993; 121: 579-587.
34. Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773.
35. Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007; 33: 273-282.
36. Gibbs NM. Point-of-care assessment of antiplatelet agents in the perioperative period: a review. Anaesth Intensive Care 2009; 37: 354-369.
37. Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
38. Chandler AB, Earhart AD, Speich HE, et al. Regulation of CD40L (CD154) and CD62P (p-selectin) Surface Expression upon GPIIb-IIIa Blockade of Platelets from Stable Coronary Artery Disease Patients. Thromb Res 2010; 125: 44-52.
39. Fox SC, May JA, Shah A, Neubert U, Heptinstall S. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009; 20: 250-259.
40. Blais N, Pharand C, Lordkipanidze M, et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102: 404-411.
41. McKenzie ME, Malinin AI, Bell CR, et al. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis 2003; 14: 249-253.
42. Hubl W, Assadian A, Lax J, et al. Assessing aspirin-induced attenuation of platelet reactivity by flow cytometry. Thromb Res 2007; 121: 135-143.
43. Panzer S, Hocker L, Koren D. Agonists-induced platelet activation varies considerably in healthy male individuals: studies by flow cytometry. Ann Hematol 2006; 85: 121-125.
44. Schmitz G, Rothe G, Ruf A, et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-896.
45. Feijge MA, van Pampus EC, Lacabaratz-Porret C, et al. Inter-individual variability in Ca2+ signalling in platelets from healthy volunteers: effects of aspirin and relationship with expression of endomembrane Ca2+-ATPases. Br J Haematol 1998; 102: 850-859.
46. Walters J, Skene D, Hampton SM, Ferns GA. Biological rhythms, endothelial health and cardiovascular disease. Med Sci Monitor 2003; 9: RA1-8.
47. Peace AJ, Egan K, Kavanagh GF, et al. Reducing intra-individual variation in platelet aggregation: implications for platelet function testing. J Thromb Haemost 2009; 7: 1941-1943.